Tinea Unguium pada Geriatri

Oleh :

dr.SK Sulistyaningrum, Sp.KK, FINSDV, IFAAD

Kejadian tinea unguium atau onikomikosis dilaporkan meningkat pada populasi geriatri dibandingkan kelompok usia lainnya. Tinea unguium merupakan infeksi pada kuku yang disebabkan oleh jamur. Pada geriatri, tinea unguium dapat menurunkan kualitas hidup, memiliki angka rekurensi yang tinggi, serta respons terhadap pengobatan yang lebih buruk. Selain itu, adanya komorbiditas dan kondisi polifarmasi pada populasi geriatri menyebabkan terapi tinea unguium lebih kompleks.[1-4]

Faktor Risiko Tinea Unguium pada Geriatri

Pada geriatri, risiko tinea unguium akan meningkat seiring dengan bertambahnya usia. Selain itu, faktor risiko lain mencakup jenis kelamin laki-laki, riwayat merokok, dan obesitas. Komorbiditas tertentu juga akan meningkatkan risiko tinea unguium pada geriatri, seperti diabetes mellitus, psoriasis, riwayat trauma pada kuku, penyakit arteri perifer, dan kondisi imunokompromais.[5,6]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Gupta AK, Venkataraman M, Talukder M. Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management. Drugs Aging. 2022 Mar 1;39(3):191–8.
2. 2Moseley I, Ragi SD, Ouellette S, Rao B. Onychomycosis in Underrepresented Groups: An All of Us Database Analysis. Review, 2022. https://www.researchsquare.com/article/rs-1624401/v1
3. All of Us Research Program Investigators, Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, Dishman E. The "All of Us" Research Program. N Engl J Med. 2019 Aug 15;381(7):668-676. doi: 10.1056/NEJMsr1809937.
4. Gupta AK, Venkataraman M, Quinlan EM. Onychomycosis in the Twenty-First Century: An Update on Epidemiology and Diagnosis. In: Bouchara JP, Nenoff P, Gupta AK, Chaturvedi V, editors. Dermatophytes and Dermatophytoses. Cham: Springer International Publishing; 2021. p. 41–64. https://doi.org/10.1007/978-3-030-67421-2_3
5. Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment. J Cutan Med Surg. 2017 Nov 1;21(6):525–39.
6. Dubljanin E, Džamić A, Vujčić I, Grujičić SŠ, Arsenijević VA, Mitrović S, et al. Epidemiology of onychomycosis in Serbia: a laboratory-based survey and risk factor identification. Mycoses. 2017;60(1):25–32.
7. Sakkas H, Kittas C, Kapnisi G, Priavali E, Kallinteri A, Bassukas ID, et al. Onychomycosis in Northwestern Greece over a 7-Year Period. Pathogens. 2020 Oct;9(10):851.
8. Petrokilidou C, Gaitanis G, Bassukas ID, Velegraki A, Guevara E, Vardaki MZ, et al. Emerging Optical Techniques for the Diagnosis of Onychomycosis. Appl Sci. 2020 Jan;10(7):2340.
9. Tsentemeidou A, Vyzantiadis TA, Kyriakou A, Sotiriadis D, Patsatsi A. Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: Results of a pilot study. Mycoses. 2017;60(12):830–5.
10. Romaszkiewicz A, Bykowska B, Zabłotna M, Sobjanek M, Sławińska M, Nowicki RJ. The prevalence and etiological factors of onychomycosis in psoriatic patients. Adv Dermatol Allergol Dermatol Alergol. 2018 Jun;35(3):309–13.
11. Gallo L, Cinelli E, Fabbrocini G, Vastarella M. A 15-year retrospective study on the prevalence of onychomycosis in psoriatic vs non-psoriatic patients: A new European shift from dermatophytes towards yeast. Mycoses. 2019;62(8):659–64.
12. Chadeganipour M, Mohammadi R. Causative Agents of Onychomycosis: A 7-Year Study. J Clin Lab Anal. 2016;30(6):1013–20.
13. Motamedi M, Ghasemi Z, Shidfar MR, Hosseinpour L, Khodadadi H, Zomorodian K, et al. Growing Incidence of Non-Dermatophyte Onychomycosis in Tehran, Iran. Jundishapur J Microbiol. 2016 Jul 26;9(8):e40543.
14. Bongomin F, Batac CR, Richardson MD, Denning DW. A Review of Onychomycosis Due to Aspergillus Species. Mycopathologia. 2018 Jun;183(3):485–93.
15. Davies JM, Sleeman KE, Leniz J, Wilson R, Higginson IJ, Verne J, et al. Socioeconomic position and use of healthcare in the last year of life: A systematic review and meta-analysis. PLOS Med. 2019 Apr 23;16(4):e1002782.
16. Gupta AK, Mays RR, Versteeg SG, Shear NH, Piguet V. Update on current approaches to diagnosis and treatment of onychomycosis. Expert Rev Anti Infect Ther. 2018 Dec 2;16(12):929–38.
17. Gupta AK, Taborda VBA, Taborda PRO, Shemer A, Summerbell RC, Nakrieko KA. High prevalence of mixed infections in global onychomycosis. PLoS ONE. 2020 Sep 29;15(9):e0239648.
18. Oliveira JT, Santos MS, Naves WV, Costa HL, Santos AS, et al. Clinical and Etiological Study of Onychomycosis in Institutionalized Elderly in Goiânia City, Goiás State, Brazil. J Geriatr Med Gerontol, 2019. 5:062. doi.org/10.23937/2469-5858/1510062
19. Gupta AK, Talukder M. Efinaconazole in Onychomycosis. Am J Clin Dermatol. 2022 Mar 1;23(2):207–18.
20. Gupta AK, Cooper EA. Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis. Skin Ther Lett. 2021 Jan 1;26(1):5–10.
21. Tiwary AK, Sapra B. High failure rate of transungal drug delivery: need for new strategies. Ther Deliv. 2017 Mar;8(5):239–42.
22. PERDOSKI. PPK Perdoski. Jakarta: PP Perdoski; 2017.
23. Shemer A, Gupta AK, Kamshov S, Babaev M, Hermush V, Farhi R, et al. Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis. J Dermatol Treat. 2021 May;32(3):310–3.
24. Lipner SR, Joseph WS, Vlahovic TC, Scher RK, Rich P, Ghannoum M, et al. Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US. J Drugs Dermatol. 2021 Oct 1;20(10):1076–84.